Clinical Trial Update: Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study of GSK2140944 for suspected or confirmed Gram-positive acute bacterial skin and skin structure infections has completed. Results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin and Skin Structure Infection

Drugs mentioned

• GSK2140944

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Bacterial | Phase 2 | Status: COMPLETED | Results posted: 2017-09-21